Stocklytics Platform
Asset logo for symbol ALT
Altimmune
ALT65
$9.23arrow_drop_down4.14%-$0.40
Asset logo for symbol ALT
ALT65

$9.23

arrow_drop_down4.14%

Performance History

Chart placeholder
Key Stats
Open$9.59
Prev. Close$9.64
EPS-1.57
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range8.96
9.93
52 Week Range2.09
14.84
Ratios
Revenue-
EBITDA Margin %-
EPS-1.57

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Altimmune (ALT)

Altimmune Inc (NASDAQ: ALT) is a clinical stage biopharmaceutical company focused on developing and commercializing novel immunotherapeutic products for infectious diseases and cancer. The company's lead product candidate is NasoVAX, a single-dose intranasal vaccine for the prevention of influenza, currently in phase 2 clinical trials. Altimmune is also developing other candidates in its pipeline, including HepTcell, a therapeutic vaccine for chronic hepatitis B, and SparVax-L, a next-generation anthrax vaccine. The company utilizes its proprietary platform technologies, including its Densigen and MimiVax platforms, to develop and produce its immunotherapeutic products.
Altimmune's stock price has experienced significant volatility in recent years. In 2017, the stock reached a peak of $35 per share, but has since declined to its current price of around $4 per share. This decline is largely attributed to the failure of the company's phase 2 clinical trial for HepTcell, which led to a significant decrease in investor confidence. However, Altimmune has since refocused its efforts on its NasoVAX program, which has shown promising results in early clinical trials. The company is confident in the potential of NasoVAX to address the significant unmet need for a universal influenza vaccine and is actively advancing the candidate through clinical development.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Vipin K. Garg Ph.D.
Headquarters
Gaithersburg
Employees
52
Exchange
NASDAQ
add Altimmune  to watchlist

Keep an eye on Altimmune

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Altimmune 's (ALT) price per share?

The current price per share for Altimmune (ALT) is $9.23. The stock has seen a price change of -$0.4 recently, indicating a -4.15% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Altimmune (ALT)?

For Altimmune (ALT), the 52-week high is $14.84, which is 60.69% from the current price. The 52-week low is $2.09, the current price is 341.87% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Altimmune (ALT) a growth stock?

Altimmune (ALT) has shown an average price growth of -2.59% over the past three years. It has received a score of 62 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Altimmune as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Altimmune (ALT) stock price performance year to date (YTD)?

As of the latest data, Altimmune (ALT) has a year-to-date price change of -12.21%. Over the past month, the stock has experienced a price change of 25.65%. Over the last three months, the change has been 44.75%. Over the past six months, the figure is 47.52%. Looking at a longer horizon, the five-year price change stands at 401.9%.
help

Is Altimmune (ALT) a profitable company?

Altimmune (ALT) has a net income of -$88.45M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -495.34K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$95.93M. Furthermore, the EBITDA is -$99.19M.
help

What is the market capitalization of Altimmune (ALT)?

Altimmune (ALT) has a market capitalization of $652.92M. The average daily trading volume is 9.28, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level